?? Elevate your research with Science 42: #DORA—now at 50% off for a limited time. This advanced #AI-driven tool from Insilico Medicine makes drafting professional #scientificdocuments faster and more efficient. Visit the DORA website to get started today: https://bit.ly/3XoW8eR #blogs #writing #academics #conferenceabstracts
Insilico Medicine
生物技术研究
Boston，Massachusetts 57,983 位关注者
#insilicomeds, #drugdiscovery, #ai, #GANs, #GANs-RL, #DL #aging, #longevity
关于我们
Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
- 网站
-
https://www.Insilico.com
Insilico Medicine的外部链接
- 所属行业
- 生物技术研究
- 规模
- 201-500 人
- 总部
- Boston，Massachusetts
- 类型
- 私人持股
- 创立
- 2014
- 领域
- artificial intelligence、deep learning、reinforcement learning、drug discovery、aging research、longevity、biomarker development、Generative adversarial networks、GANs和GANs-RL
地点
Insilico Medicine员工
动态
-
???? Using Amazon SageMaker, Insilico has improved its model training capabilities, enhancing its solutions for accelerating #drugdiscovery. Insilico now has two systems that benefit from the advanced models that were trained on Amazon SageMaker: PandaOmics, a solution that empowers researchers to identify potential therapeutic targets, and Chemistry42, a comprehensive #small-molecule drug discovery platform. Using AI and ML on Amazon Web Services (AWS), Insilico will continue its groundbreaking work in discovering new targets and developing innovative molecules in pursuit of life-changing drugs to combat diseases. “Our mission is to extend healthy, productive longevity for everyone,” says Petrina Kamya, Ph.D., global head of AI platforms for Insilico. “That is what we set our minds to every day when we come into work.” Read the full case study here: https://lnkd.in/ebRq_i7R
-
???? Prague.bio begins today! Catch Jan Szollos, MBA onsite for all things #PharmaAI.
Insilico Medicine is now back at the Prague.bio conference. Same as last year, the event is taking place in a beautiful location in the heart of Prague. It's also great to catch up with the growing community of #pharma, #biotech, and #ai #drugdiscovery companies and investors active in the CEE region. Kudos to the organizers, sponsors, and supporters! Jiri Fusek SanaClis i&i Biotech Fund Nicolas Beuzen Kamil Kuca Ján Kme?ko
-
-
https://lnkd.in/euQ-wgKx ?? Don't miss this important discussion on #GenerativeAI in Drug Discovery and #longevity, featuring Alex Wang and Alex Zhavoronkov!
Learn AI Together - I share my learning journey into AI and Data Science here, 90% buzzword-free. Follow me and let's grow together!
Join us for a live interview on Generative AI in Drug Discovery & Longevity. I invited Dr.Alex Zhavoronkov, Founder and CEO at Insilico Medicine, who's been a pioneer in this space for over two decades. With a Ph.D. in Biotechnology, Alex has been at the forefront of combining bioinformatics with deep learning, specializing in longevity. He's published numerous papers in top-tier scientific journals like Nature and Science Translational Medicine. After announcing Insilico Medicine at the NVIDIA GTC conference in 2015, the company has made remarkable breakthroughs: By 2019, Insilico validated its Chemistry42 platform in Nature Biotechnology, demonstrating that they could use deep learning models to produce a de novo small molecule that was tested and validated in animal studies. Today, the company has: - A lead AI-designed drug in Phase II trials for idiopathic pulmonary fibrosis - Nine compounds received IND approval - World leading end-to-end Generative AI platform across Biology, Chemistry Medicine and Science - 31 drugs in the pipeline, targeting cancer, fibrosis, immunology, IBD, and COVID-19 … In our conversation, we'll dive into Dr. Zhavoronkov's vision, latest research, and innovations in longevity, and explore the crucial role Generative AI plays in shaping the future of medicine. Don't miss out – join us live for this insightful conversation! ? Make sure to subscribe (click '????????????') to receive the recording. #artificialintelligence #generativeai #technology #healthcare #innovation
Join us | GenAI in Drug Discovery & Longevity with Dr. Alex Zhavoronkov
www.dhirubhai.net
-
?? Tutorial: How to generate a #reviewpaper using Science42: #DORA (Draft Outline Research Assistant) Get a deeper look at how the review papers are created below: #publications #casestudies
-
Just in case you missed the news. Dose-dependent improvements in FVC after 12 weeks is a remarkable achievement for any biotech. And since I am familiar with how the drug was discovered and the technology risks we had to take - I still can not believe it all worked to get us to this point. Huge thanks to the team!
-
-
Our team is onsite at #EUROQSAR 2024! Insilico Medicine Co-Founder and President, Alex Aliper, PhD, will be at the 24th EUROQSAR symposium this week in Barcelona, Spain joined by Arkadii Lin, Team Lead in #Chemoinformatics. The presentation will take place on September 26: #Chemistry42: Combining #GenerativeChemistry and Next-Generation Binding Free Energy Engine for Lead Identification and #Optimization (SL14) Be sure to visit Poster #P126 onsite and don't miss this Thursday's presentation! https://bit.ly/3zvxzVC
-
-
?? Insilico reports positive initial trial data for AI-designed #IPF drug, the latest from Longevity.Technology The 12-week Phase 2a clinical trial enrolled 71 patients across 21 sites in China, with participants receiving either a placebo or varying doses of the drug: 30 mg once or twice daily, or 60 mg once daily. The trial’s primary endpoint was safety, and secondary efficacy endpoints included changes in lung function. The results indicated that the drug was well-tolerated across all dose levels, with the highest dose group (60 mg once daily) showing the most significant improvement in FVC. “These results are very encouraging, particularly the dose-dependent response in FVC,” said trial investigator Dr Toby M Maher, an expert in interstitial lung disease. “IPF is a devastating disease, and seeing improvements in lung function over just 12 weeks of treatment is a promising indication that ISM001-055 may provide a new therapeutic option for patients.” Read the full article here: https://lnkd.in/eg45xee2 #GenAIPhase2 #Phase2AI
Insilico reports positive initial trial data for AI-designed IPF drug
https://longevity.technology
-
Join Alex Zhavoronkov, PhD, as part of the #ScienceSummit UNGA 2024. https://bit.ly/4gE4xDZ Be inspired by today's leading voices in #Science and #Innovation and discover how cutting-edge technology, global cooperation and #partnerships, inclusive social projects, and sustainable financing are driving progress toward achieving the UN #Sustainable Development Goals.
-
-
?? Here's a simple rule in today's #generativeAI world: validation is the unavoidable key point on the path to success. After we bridged the intersection of the two major fields in drug discovery through #AI, a big challenge arose. Once you scale up and try to utilize AI for drug discovery, you definitely need a different set of expertise. You need a group of drug hunters who can filter and analyze the results produced by AI, and make the final leap. At the center of this group is Dr. Ren. Under his leadership, we have combined the best of artificial intelligence and human intelligence. In this video, we revealed the real-time demo of our #biology and #chemistry AI platform, which has provided a comprehensive AI-powered end-to-end solution for drug discovery. That allows essentially anyone with the tool to streamline the drug development process, reducing time and cost while increasing the success rate.